keratosis: A skin disorder consisting of hypertrophy of the stratum corneum of the skin.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
81 |
4. Check minimum number of eventsNone |
81 |
5. Include endpointsNone |
81 |
6. Filter based on genotype QC (FinnGen only) |
81 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E87
- Name in latin
- Alkalosis
Similar endpoints
↥List of similar endpoints to
Alkalosis
based on the number of shared cases.
Similar with more cases:
- Other disorders of fluid, electrolyte and acid-base balance
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 798 | 411 | 378 |
| Only index persons | 681 | 363 | 318 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 61.60 | 64.07 | 58.89 |
| Only index persons | 61.83 | 64.41 | 58.89 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 81 | 40 | 41 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | 58.04 | 54.15 | 61.85 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 72
- Matched controls
- 718
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E87.3
ICD-10 Finland
Alkalosis
+∞
98.1
70
*
E87.6
ICD-10 Finland
Hypokalaemia
353.2
39.0
36
*
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
96.9
19.9
21
*
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
22.5
14.0
20
12
K92.0
ICD-10 Finland
Haematemesis
47.2
10.3
12
*
F10.30
ICD-10 Finland
Withdrawal symptoms caused by alcohol uncomplicated
+∞
9.6
9
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
5.2
9.0
33
100
R11
ICD-10 Finland
Nausea and vomiting
10.7
8.9
17
20
F10.24
ICD-10 Finland
Alcohol depence active use
101.4
8.6
9
*
E87.8
ICD-10 Finland
Other disorders of electrolyte and fluid balance, not elsewhere classified
+∞
7.4
7
*
JN3AD
NOMESCO Finland
Abdominal CT examination
9.2
7.4
15
20
WX892
NOMESCO Finland
Monitored bed care
9.9
7.2
14
17
AA1AD
NOMESCO Finland
CT of head and brain
4.8
7.2
26
75
N17.9
ICD-10 Finland
Acute renal failure, unspecified
19.0
7.0
10
6
F10.00
ICD-10 Finland
Alcohol-related acute intoxication uncomplicated
19.0
7.0
10
6
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.0
6.8
34
132
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.1
6.8
33
124
N07BB01
ATC
disulfiram; oral
12.7
6.6
11
10
E86
ICD-10 Finland
Volume depletion
76.3
6.5
7
*
E10.1
ICD-10 Finland
Type 1 diabetes mellitus, With ketoacidosis
+∞
6.3
6
*
SPAT1265
SPAT
Breathalyser
+∞
6.3
6
*
WX882
NOMESCO Finland
High dependency care
14.2
6.3
10
8
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.8
6.1
21
57
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.6
6.1
22
63
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
48
82
12.91
31.30
8.0
4.0
0.8
0.8
mmol/l
0.13
48
76
43
129
5.97
14.67
3.4
2.0
3.1
3.3
mg/l
0.22
38
110
19
25
9.62
14.20
16.2
6.3
0.8
0.6
%
0.62
19
25
19
26
9.24
13.76
16.1
5.2
1.6
1.7
%
0.04
19
26
60
258
6.11
13.00
22.2
5.7
1.2
1.2
mmol/l
1.97
53
219
18
25
8.97
12.83
16.9
6.4
93.5
93.1
%
0.07
18
25
17
22
9.51
12.80
11.1
2.8
29.1
23.5
mmol/l
1.94
17
22
36
106
5.31
12.20
2.2
1.8
1303.4
1280.7
nmol/l
0.05
29
80
17
26
8.01
11.12
11.4
1.6
118.8
125.8
g/l
0.41
17
26
17
31
6.67
9.43
1.8
1.3
—
—
—
0
0
42
168
4.12
9.12
3.4
1.8
202.4
169.9
u/l
0.23
42
154
12
15
9.22
9.11
14.6
3.1
30.7
24.7
mmol/l
1.45
12
15
30
94
4.48
9.07
1.9
1.8
—
—
—
0
0
31
101
4.35
8.89
4.6
3.5
2.5
2.5
mmol/l
0.09
26
83
47
209
3.98
8.66
7.5
3.6
52.6
50.6
ng/l
0.04
35
146
14
23
7.15
8.49
13.0
1.5
1.4
1.2
%
0.19
14
23
49
228
3.91
8.36
4.7
2.0
70.6
76.1
nmol/l
0.73
44
196
14
24
6.84
8.16
15.0
1.7
47.5
44.5
%
0.14
14
24
14
25
6.56
7.85
14.8
1.8
26.8
25.4
mmol/l
0.21
14
25
17
38
5.40
7.59
2.6
1.7
—
—
—
0
0
32
118
3.83
7.58
5.4
2.3
—
—
—
0
0
31
112
3.86
7.56
3.0
1.6
1.2
0.9
mg/l
0.41
25
82
46
216
3.61
7.53
6.1
2.7
—
—
—
0
0
14
27
6.06
7.26
1.7
1.6
—
—
—
0
0
22
65
4.27
7.02
1.7
1.6
—
—
—
0
0
47
232
3.44
6.96
3.0
1.9
89.9
97.8
pmol/l
0.65
31
117
22
66
4.20
6.87
1.7
1.7
—
—
—
0
0
68
455
4.08
5.63
25.3
7.6
93.9
76.4
u/l
1.03
68
415
9
8
12.45
5.43
1.7
2.0
—
—
—
0
0
13
33
4.50
4.93
1.8
1.9
55.8
71.8
ml/min/173m2
—
5
13
9
10
9.95
4.92
1.2
1.1
—
—
—
0
0
24
103
2.89
4.17
3.5
2.5
2.6
0.7
e6/l
0.41
13
61
43
255
2.46
3.85
6.3
4.4
—
—
—
0
0
25
122
2.52
3.33
2.6
1.8
684.8
467.3
pmol/l
0.47
19
102
21
97
2.57
3.11
3.6
2.6
8.5
1.7
e6/l
—
10
56
8
18
4.81
2.87
1.9
2.7
11.6
10.0
g/l
—
8
18
8
19
4.55
2.76
1.9
2.7
—
—
—
0
0
44
293
2.10
2.70
4.7
3.1
0.0
0.0
estimate
—
9
60
44
296
2.07
2.60
5.7
3.9
0.0
0.0
estimate
—
10
60
8
21
4.11
2.54
2.0
2.5
—
—
—
0
0
27
152
2.16
2.53
4.4
2.5
385.8
5188.2
umol/l
0.74
27
130
44
299
2.03
2.50
4.7
3.1
0.0
0.0
estimate
—
7
59
73
622
2.76
2.34
49.9
12.7
27.4
20.8
mg/l
1.16
68
457
7
18
4.15
2.31
2.1
2.3
—
—
—
0
0
8
24
3.58
2.24
1.6
1.5
—
—
—
0
0
5
9
5.83
2.24
5.8
2.9
233.6
175.1
%
—
5
9
6
14
4.54
2.19
2.2
1.8
—
—
—
0
0
6
15
4.23
2.08
2.0
3.1
0.0
0.0
g/l
—
6
15
6
15
4.23
2.08
2.0
3.1
0.0
0.0
g/l
—
6
15
6
15
4.23
2.08
2.0
3.1
39.6
37.9
g/l
—
6
15
6
16
3.96
1.97
2.0
3.1
0.0
0.0
g/l
—
6
16
6
16
3.96
1.97
1.0
1.3
—
—
—
0
0
5
11
4.76
1.97
6.0
1.7
88.4
86.3
%
—
5
11
26
158
1.95
1.94
6.2
3.6
0.0
0.0
estimate
—
8
61
20
111
2.06
1.90
1.7
1.2
0.9
0.7
u/ml
—
7
24
5
12
4.36
1.85
1.8
1.3
—
—
—
0
0
5
12
4.36
1.85
1.8
1.3
—
—
—
0
0
6
18
3.51
1.78
3.8
1.3
—
—
—
0
0
5
13
4.02
1.74
2.0
1.2
—
—
—
0
0
5
13
4.02
1.74
2.0
1.2
—
—
—
0
0
5
13
4.02
1.74
1.4
1.7
—
—
—
0
0
5
16
3.26
1.46
3.2
2.4
—
—
—
0
0
72
642
2.09
1.39
68.9
13.8
138.1
139.9
mmol/l
4.76
72
620
72
646
2.03
1.26
68.3
13.8
3.9
4.0
mmol/l
2.17
72
624
6
26
2.41
1.21
2.7
1.6
—
—
—
0
0
5
21
2.47
1.10
7.6
2.4
18.0
116.3
u/ml
—
5
16
67
598
1.70
0.98
44.7
12.3
78.3
82.8
ml/min/173m2
0.63
61
482
5
101
0.46
0.97
1.6
1.3
—
—
—
0
0
31
235
1.52
0.97
5.6
3.1
—
—
—
0
0
11
66
1.77
0.83
4.4
3.5
—
—
—
0
0
0
24
0.00
0.80
0.0
1.3
—
203.0
—
0
10
72
668
1.70
0.79
59.2
14.5
93.9
76.8
umol/l
1.48
72
668
15
102
1.58
0.74
1.3
1.3
56.0
27.7
iu/ml
—
7
39
67
620
1.47
0.58
5.0
4.1
4.2
4.7
mmol/l
2.84
61
568
66
617
1.38
0.46
5.0
4.0
1.4
1.5
mmol/l
0.14
61
561
0
19
0.00
0.39
0.0
1.4
—
—
—
0
0
9
70
1.32
0.38
20.0
6.2
—
—
—
0
0
13
101
1.34
0.34
1.2
1.2
1.9
11.7
u/ml
—
6
30
63
600
1.23
0.26
5.0
3.6
1.3
1.3
mmol/l
0.28
58
545
42
388
1.17
0.24
2.9
3.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
6
57
1.06
0.09
2.3
1.9
—
—
—
0
0
20
191
1.06
0.03
6.2
4.3
20.3
21.9
%
—
7
83
10
106
0.94
0.01
1.4
1.6
—
—
—
0
0
61
616
0.96
0.00
6.3
4.3
6.4
5.9
mmol/l
1.12
55
561
6
65
0.92
0.00
2.3
2.1
—
—
—
0
0
0
6
0.00
0.00
0.0
3.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
13.0
—
0
7
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_ALKALOSIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ALKALOSIS | 3.225 [1.93, 5.39] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.087 |
During the follow-up period (1.1.1998 — 31.12.2019), 110 out of 300 females with E4_ALKALOSIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ALKALOSIS | 4.629 [2.28, 9.39] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.034 |
During the follow-up period (1.1.1998 — 31.12.2019), 90 out of 246 males with E4_ALKALOSIS died.
Mortality risk
Mortality risk for people of age
years, who have E4_ALKALOSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.279% | 1.062% |
| 5 | 1.763% | 5.621% |
| 10 | 4.404% | 13.68% |
| 15 | 8.305% | 24.568% |
| 20 | 13.736% | 38.647% |
Relationships between endpoints
↥Index endpoint: E4_ALKALOSIS – Alkalosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data